Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Udaya Bhaskar Kompella

TitleProfessor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOP-Administration
Phone303/724-4028

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Tran J, Craven C, Wabner K, Schmit J, Matter B, Kompella U, Grossniklaus HE, Olsen TW. A Pharmacodynamic Analysis of Choroidal Neovascularization in a Porcine Model Using Three Targeted Drugs. Invest Ophthalmol Vis Sci. 2017 Jul 01; 58(9):3732-3740. PMID: 28738417.
      View in: PubMed
    2. Muralidharan R, Babu A, Amreddy N, Srivastava A, Chen A, Zhao YD, Kompella UB, Munshi A, Ramesh R. Tumor-targeted Nanoparticle Delivery of HuR siRNA Inhibits Lung Tumor Growth In Vitro and In Vivo By Disrupting the Oncogenic Activity of the RNA-binding Protein HuR. Mol Cancer Ther. 2017 Aug; 16(8):1470-1486. PMID: 28572169.
      View in: PubMed
    3. Yavuz B, Kompella UB. Ocular Drug Delivery. Handb Exp Pharmacol. 2017; 242:57-93. PMID: 27783270.
      View in: PubMed
    4. Chaiyasan W, Praputbut S, Kompella UB, Srinivas SP, Tiyaboonchai W. Penetration of mucoadhesive chitosan-dextran sulfate nanoparticles into the porcine cornea. Colloids Surf B Biointerfaces. 2017 Jan 01; 149:288-296. PMID: 27771493.
      View in: PubMed
    5. Panda JJ, Yandrapu S, Kadam RS, Chauhan VS, Kompella UB. Retracted: Self-assembled Phenylalanine-a,ß-dehydrophenylalanine Nanotubes for Sustained Intravitreal Delivery of a Multi-targeted Tyrosine Kinase Inhibitor. J Control Release. 2016 Sep 10; 237:186. PMID: 27521264.
      View in: PubMed
    6. Muralidharan R, Babu A, Amreddy N, Basalingappa K, Mehta M, Chen A, Zhao YD, Kompella UB, Munshi A, Ramesh R. Folate receptor-targeted nanoparticle delivery of HuR-RNAi suppresses lung cancer cell proliferation and migration. J Nanobiotechnology. 2016 Jun 21; 14(1):47. PMID: 27328938; PMCID: PMC4915183.
    7. Lee JH, McBrayer MK, Wolfe DM, Haslett LJ, Kumar A, Sato Y, Lie PP, Mohan P, Coffey EE, Kompella U, Mitchell CH, Lloyd-Evans E, Nixon RA. Presenilin 1 Maintains Lysosomal Ca(2+) Homeostasis via TRPML1 by Regulating vATPase-Mediated Lysosome Acidification. Cell Rep. 2015 Sep 01; 12(9):1430-44. PMID: 26299959; PMCID: PMC4558203.
    8. Wang Z, Cheng R, Lee K, Tyagi P, Ding L, Kompella UB, Chen J, Xu X, Ma JX. Nanoparticle-mediated expression of a Wnt pathway inhibitor ameliorates ocular neovascularization. Arterioscler Thromb Vasc Biol. 2015 Apr; 35(4):855-64. PMID: 25657312; PMCID: PMC4376607.
    9. Kulkarni SS, Kompella UB. Potential drug delivery approaches for XFS-associated and XFS-associated glaucoma. J Glaucoma. 2014 Oct-Nov; 23(8 Suppl 1):S77-9. PMID: 25275914.
      View in: PubMed
    10. Clapp T, Munks MW, Trivedi R, Kompella UB, Braun LJ. Freeze-thaw stress of Alhydrogel ® alone is sufficient to reduce the immunogenicity of a recombinant hepatitis B vaccine containing native antigen. Vaccine. 2014 Jun 24; 32(30):3765-71. PMID: 24856785.
      View in: PubMed
    11. Rowe-Rendleman CL, Durazo SA, Kompella UB, Rittenhouse KD, Di Polo A, Weiner AL, Grossniklaus HE, Naash MI, Lewin AS, Horsager A, Edelhauser HF. Drug and gene delivery to the back of the eye: from bench to bedside. Invest Ophthalmol Vis Sci. 2014 Apr 28; 55(4):2714-30. PMID: 24777644; PMCID: PMC4004426.
    12. Rajashekhar G, Shivanna M, Kompella UB, Wang Y, Srinivas SP. Role of MMP-9 in the breakdown of barrier integrity of the corneal endothelium in response to TNF-a. Exp Eye Res. 2014 May; 122:77-85. PMID: 24667088.
      View in: PubMed
    13. Kim SJ, Toma H, Shah R, Kompella UB, Vooturi SK, Sheng J. The safety, pharmacokinetics, and efficacy of intraocular celecoxib. Invest Ophthalmol Vis Sci. 2014 Mar 10; 55(3):1409-18. PMID: 24458149; PMCID: PMC3954004.
    14. Cruz NM, Yuan Y, Leehy BD, Baid R, Kompella U, DeAngelis MM, Escher P, Haider NB. Modifier genes as therapeutics: the nuclear hormone receptor Rev Erb alpha (Nr1d1) rescues Nr2e3 associated retinal disease. PLoS One. 2014; 9(1):e87942. PMID: 24498227; PMCID: PMC3909326.
    15. Yandrapu SK, Upadhyay AK, Petrash JM, Kompella UB. Nanoparticles in porous microparticles prepared by supercritical infusion and pressure quench technology for sustained delivery of bevacizumab. Mol Pharm. 2013 Dec 02; 10(12):4676-86. PMID: 24131101; PMCID: PMC4004035.
    16. Panda JJ, Yandrapu S, Kadam RS, Chauhan VS, Kompella UB. Self-assembled phenylalanine-a,ß-dehydrophenylalanine nanotubes for sustained intravitreal delivery of a multi-targeted tyrosine kinase inhibitor. J Control Release. 2013 12 28; 172(3):1151-60. PMID: 24075925.
      View in: PubMed
    17. Rao VR, Upadhyay AK, Kompella UB. pH shift assembly of adenoviral serotype 5 capsid protein nanosystems for enhanced delivery of nanoparticles, proteins and nucleic acids. J Control Release. 2013 Nov 28; 172(1):341-50. PMID: 24004886.
      View in: PubMed
    18. Tari SR, Youssif M, Samson CM, Harris RL, Lin CM, Kompella UB, Antonetti DA, Barile GR. Polychromatic angiography for the assessment of VEGF-induced BRB dysfunction in the rabbit retina. Invest Ophthalmol Vis Sci. 2013 Aug 15; 54(8):5550-8. PMID: 23882687.
      View in: PubMed
    19. Chowdhury S, Guha R, Trivedi R, Kompella UB, Konar A, Hazra S. Pirfenidone nanoparticles improve corneal wound healing and prevent scarring following alkali burn. PLoS One. 2013; 8(8):e70528. PMID: 23940587; PMCID: PMC3734236.
    20. Tyagi P, Barros M, Stansbury JW, Kompella UB. Light-activated, in situ forming gel for sustained suprachoroidal delivery of bevacizumab. Mol Pharm. 2013 Aug 05; 10(8):2858-67. PMID: 23734705; PMCID: PMC4003910.
    21. Kadam RS, Williams J, Tyagi P, Edelhauser HF, Kompella UB. Suprachoroidal delivery in a rabbit ex vivo eye model: influence of drug properties, regional differences in delivery, and comparison with intravitreal and intracameral routes. Mol Vis. 2013; 19:1198-210. PMID: 23734089; PMCID: PMC3669536.
    22. Kadam RS, Ramamoorthy P, LaFlamme DJ, McKinsey TA, Kompella UB. Hypoxia alters ocular drug transporter expression and activity in rat and calf models: implications for drug delivery. Mol Pharm. 2013 Jun 03; 10(6):2350-61. PMID: 23607566; PMCID: PMC3973437.
    23. Bargagna-Mohan P, Deokule SP, Thompson K, Wizeman J, Srinivasan C, Vooturi S, Kompella UB, Mohan R. Withaferin A effectively targets soluble vimentin in the glaucoma filtration surgical model of fibrosis. PLoS One. 2013; 8(5):e63881. PMID: 23667686; PMCID: PMC3648549.
    24. Baid R, Upadhyay AK, Shinohara T, Kompella UB. Biosynthesis, characterization, and efficacy in retinal degenerative diseases of lens epithelium-derived growth factor fragment (LEDGF1-326), a novel therapeutic protein. J Biol Chem. 2013 Jun 14; 288(24):17372-83. PMID: 23640891; PMCID: PMC3682538.
    25. Sreekumar PG, Chothe P, Sharma KK, Baid R, Kompella U, Spee C, Kannan N, Manh C, Ryan SJ, Ganapathy V, Kannan R, Hinton DR. Antiapoptotic properties of a-crystallin-derived peptide chaperones and characterization of their uptake transporters in human RPE cells. Invest Ophthalmol Vis Sci. 2013 Apr 17; 54(4):2787-98. PMID: 23532520; PMCID: PMC3632268.
    26. Kompella UB, Amrite AC, Pacha Ravi R, Durazo SA. Nanomedicines for back of the eye drug delivery, gene delivery, and imaging. Prog Retin Eye Res. 2013 Sep; 36:172-98. PMID: 23603534; PMCID: PMC3926814.
    27. Dhanda DS, Tyagi P, Mirvish SS, Kompella UB. Supercritical fluid technology based large porous celecoxib-PLGA microparticles do not induce pulmonary fibrosis and sustain drug delivery and efficacy for several weeks following a single dose. J Control Release. 2013 Jun 28; 168(3):239-50. PMID: 23562638.
      View in: PubMed
    28. Luo L, Zhang X, Hirano Y, Tyagi P, Barabás P, Uehara H, Miya TR, Singh N, Archer B, Qazi Y, Jackman K, Das SK, Olsen T, Chennamaneni SR, Stagg BC, Ahmed F, Emerson L, Zygmunt K, Whitaker R, Mamalis C, Huang W, Gao G, Srinivas SP, Krizaj D, Baffi J, Ambati J, Kompella UB, Ambati BK. Targeted intraceptor nanoparticle therapy reduces angiogenesis and fibrosis in primate and murine macular degeneration. ACS Nano. 2013 Apr 23; 7(4):3264-75. PMID: 23464925; PMCID: PMC3634882.
    29. Kompella UB. Nanotechnology and drug delivery. J Ocul Pharmacol Ther. 2013 Mar; 29(2):89. PMID: 23485089.
      View in: PubMed
    30. Aquilante CL, Kosmiski LA, Bourne DW, Bushman LR, Daily EB, Hammond KP, Hopley CW, Kadam RS, Kanack AT, Kompella UB, Le M, Predhomme JA, Rower JE, Sidhom MS. Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone. Br J Clin Pharmacol. 2013 Jan; 75(1):217-26. PMID: 22625877; PMCID: PMC3555061.
    31. Kadam R, Bourne D, Kompella U, Aquilante C. Effect of Cytochrome P450 2C8*3 on the Population Pharmacokinetics of Pioglitazone in Healthy Caucasian Volunteers. Biol Pharm Bull. 2013; 36(2):245-51. PMID: 23370354.
      View in: PubMed
    32. Yandrapu S, Kompella UB. Development of sustained-release microspheres for the delivery of SAR 1118, an LFA-1 antagonist intended for the treatment of vascular complications of the eye. J Ocul Pharmacol Ther. 2013 Mar; 29(2):236-48. PMID: 23256487; PMCID: PMC3601676.
    33. Baltazar GC, Guha S, Lu W, Lim J, Boesze-Battaglia K, Laties AM, Tyagi P, Kompella UB, Mitchell CH. Acidic nanoparticles are trafficked to lysosomes and restore an acidic lysosomal pH and degradative function to compromised ARPE-19 cells. PLoS One. 2012; 7(12):e49635. PMID: 23272048; PMCID: PMC3525582.
    34. Trivedi R, Redente EF, Thakur A, Riches DW, Kompella UB. Local delivery of biodegradable pirfenidone nanoparticles ameliorates bleomycin-induced pulmonary fibrosis in mice. Nanotechnology. 2012 Dec 21; 23(50):505101. PMID: 23186914.
      View in: PubMed
    35. Kadam RS, Vooturi SK, Kompella UB. Immunohistochemical and functional characterization of peptide, organic cation, neutral and basic amino acid, and monocarboxylate drug transporters in human ocular tissues. Drug Metab Dispos. 2013 Feb; 41(2):466-74. PMID: 23169611; PMCID: PMC3558866.
    36. Tyagi P, Kadam RS, Kompella UB. Comparison of suprachoroidal drug delivery with subconjunctival and intravitreal routes using noninvasive fluorophotometry. PLoS One. 2012; 7(10):e48188. PMID: 23118950; PMCID: PMC3485142.
    37. Kadam RS, Scheinman RI, Kompella UB. Pigmented-MDCK (P-MDCK) cell line with tunable melanin expression: an in vitro model for the outer blood-retinal barrier. Mol Pharm. 2012 Nov 05; 9(11):3228-35. PMID: 23003570; PMCID: PMC3926804.
    38. Vooturi SK, Kadam RS, Kompella UB. Transporter targeted gatifloxacin prodrugs: synthesis, permeability, and topical ocular delivery. Mol Pharm. 2012 Nov 05; 9(11):3136-46. PMID: 23003105; PMCID: PMC3926802.
    39. Yang H, Tyagi P, Kadam RS, Holden CA, Kompella UB. Hybrid dendrimer hydrogel/PLGA nanoparticle platform sustains drug delivery for one week and antiglaucoma effects for four days following one-time topical administration. ACS Nano. 2012 Sep 25; 6(9):7595-606. PMID: 22876910.
      View in: PubMed
    40. Tewari-Singh N, Jain AK, Inturi S, Ammar DA, Agarwal C, Tyagi P, Kompella UB, Enzenauer RW, Petrash JM, Agarwal R. Silibinin, dexamethasone, and doxycycline as potential therapeutic agents for treating vesicant-inflicted ocular injuries. Toxicol Appl Pharmacol. 2012 Oct 01; 264(1):23-31. PMID: 22841772; PMCID: PMC3928638.
    41. Kadam RS, Tyagi P, Edelhauser HF, Kompella UB. RETRACTED: Influence of choroidal neovascularization and biodegradable polymeric particle size on transscleral sustained delivery of triamcinolone acetonide. Int J Pharm. 2012 09 15; 434(1-2):140-7. PMID: 22633904; PMCID: PMC3573139.
    42. Qazi Y, Stagg B, Singh N, Singh S, Zhang X, Luo L, Simonis J, Kompella UB, Ambati BK. Nanoparticle-mediated delivery of shRNA.VEGF-a plasmids regresses corneal neovascularization. Invest Ophthalmol Vis Sci. 2012 May 14; 53(6):2837-44. PMID: 22467572; PMCID: PMC3367470.
    43. Cho YK, Uehara H, Young JR, Tyagi P, Kompella UB, Zhang X, Luo L, Singh N, Archer B, Ambati BK. Flt23k nanoparticles offer additive benefit in graft survival and anti-angiogenic effects when combined with triamcinolone. Invest Ophthalmol Vis Sci. 2012 Apr 30; 53(4):2328-36. PMID: 22427553; PMCID: PMC3995562.
    44. Kadam RS, Bourne DW, Kompella UB. Nano-advantage in enhanced drug delivery with biodegradable nanoparticles: contribution of reduced clearance. Drug Metab Dispos. 2012 Jul; 40(7):1380-8. PMID: 22498894; PMCID: PMC3382836.
    45. Durairaj C, Chastain JE, Kompella UB. Intraocular distribution of melanin in human, monkey, rabbit, minipig and dog eyes. Exp Eye Res. 2012 May; 98:23-7. PMID: 22440812; PMCID: PMC3358346.
    46. Malik P, Kadam RS, Cheruvu NP, Kompella UB. Hydrophilic prodrug approach for reduced pigment binding and enhanced transscleral retinal delivery of celecoxib. Mol Pharm. 2012 Mar 05; 9(3):605-14. PMID: 22256989; PMCID: PMC3311925.
    47. Durazo SA, Kompella UB. Functionalized nanosystems for targeted mitochondrial delivery. Mitochondrion. 2012 Mar; 12(2):190-201. PMID: 22138492; PMCID: PMC3299903.
    48. Scheinman RI, Trivedi R, Vermillion S, Kompella UB. Functionalized STAT1 siRNA nanoparticles regress rheumatoid arthritis in a mouse model. Nanomedicine (Lond). 2011 Dec; 6(10):1669-82. PMID: 22087799.
      View in: PubMed
    49. Holden CA, Tyagi P, Thakur A, Kadam R, Jadhav G, Kompella UB, Yang H. Polyamidoamine dendrimer hydrogel for enhanced delivery of antiglaucoma drugs. Nanomedicine. 2012 Jul; 8(5):776-83. PMID: 21930109.
      View in: PubMed
    50. Thakur A, Scheinman RI, Rao VR, Kompella UB. Pazopanib, a multitargeted tyrosine kinase inhibitor, reduces diabetic retinal vascular leukostasis and leakage. Microvasc Res. 2011 Nov; 82(3):346-50. PMID: 21945644; PMCID: PMC3233473.
    51. Baid R, Scheinman RI, Shinohara T, Singh DP, Kompella UB. LEDGF(1-326) decreases P23H and wild type rhodopsin aggregates and P23H rhodopsin mediated cell damage in human retinal pigment epithelial cells. PLoS One. 2011; 6(9):e24616. PMID: 21915354; PMCID: PMC3168525.
    52. Jin J, Zhou KK, Park K, Hu Y, Xu X, Zheng Z, Tyagi P, Kompella UB, Ma JX. Anti-inflammatory and antiangiogenic effects of nanoparticle-mediated delivery of a natural angiogenic inhibitor. Invest Ophthalmol Vis Sci. 2011 Aug 05; 52(9):6230-7. PMID: 21357401; PMCID: PMC3176002.
    53. Durazo SA, Kadam RS, Drechsel D, Patel M, Kompella UB. Brain mitochondrial drug delivery: influence of drug physicochemical properties. Pharm Res. 2011 Nov; 28(11):2833-47. PMID: 21796482.
      View in: PubMed
    54. Kadam RS, Cheruvu NP, Edelhauser HF, Kompella UB. Sclera-choroid-RPE transport of eight ß-blockers in human, bovine, porcine, rabbit, and rat models. Invest Ophthalmol Vis Sci. 2011 Jul 23; 52(8):5387-99. PMID: 21282583; PMCID: PMC3176076.
    55. Vasireddy V, Chavali VR, Joseph VT, Kadam R, Lin JH, Jamison JA, Kompella UB, Reddy GB, Ayyagari R. Rescue of photoreceptor degeneration by curcumin in transgenic rats with P23H rhodopsin mutation. PLoS One. 2011; 6(6):e21193. PMID: 21738619; PMCID: PMC3126808.
    56. Kadam RS, Jadhav G, Ogidigben M, Kompella UB. Ocular pharmacokinetics of dorzolamide and brinzolamide after single and multiple topical dosing: implications for effects on ocular blood flow. Drug Metab Dispos. 2011 Sep; 39(9):1529-37. PMID: 21673129; PMCID: PMC3164276.
    57. Pan CK, Durairaj C, Kompella UB, Agwu O, Oliver SC, Quiroz-Mercado H, Mandava N, Olson JL. Comparison of long-acting bevacizumab formulations in the treatment of choroidal neovascularization in a rat model. J Ocul Pharmacol Ther. 2011 Jun; 27(3):219-24. PMID: 21574814; PMCID: PMC3107977.
    58. Thakur A, Kadam R, Kompella UB. Trabecular meshwork and lens partitioning of corticosteroids: implications for elevated intraocular pressure and cataracts. Arch Ophthalmol. 2011 07; 129(7):914-20. PMID: 21402977; PMCID: PMC3407594.
    59. Thakur A, Kadam RS, Kompella UB. Influence of drug solubility and lipophilicity on transscleral retinal delivery of six corticosteroids. Drug Metab Dispos. 2011 May; 39(5):771-81. PMID: 21346004; PMCID: PMC3082374.
    60. Pfeifer T, Buchebner M, Chandak PG, Patankar J, Kratzer A, Obrowsky S, Rechberger GN, Kadam RS, Kompella UB, Kostner GM, Kratky D, Levak-Frank S. Synthetic LXR agonist suppresses endogenous cholesterol biosynthesis and efficiently lowers plasma cholesterol. Curr Pharm Biotechnol. 2011 Feb 01; 12(2):285-92. PMID: 21190543; PMCID: PMC3163291.
    61. Shelke NB, Kadam R, Tyagi P, Rao VR, Kompella UB. Intravitreal Poly(L-lactide) Microparticles Sustain Retinal and Choroidal Delivery of TG-0054, a Hydrophilic Drug Intended for Neovascular Diseases. Drug Deliv Transl Res. 2011 Feb; 1(1):76-90. PMID: 22888471; PMCID: PMC3416885.
    62. Edelhauser HF, Rowe-Rendleman CL, Robinson MR, Dawson DG, Chader GJ, Grossniklaus HE, Rittenhouse KD, Wilson CG, Weber DA, Kuppermann BD, Csaky KG, Olsen TW, Kompella UB, Holers VM, Hageman GS, Gilger BC, Campochiaro PA, Whitcup SM, Wong WT. Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Invest Ophthalmol Vis Sci. 2010 Nov; 51(11):5403-20. PMID: 20980702; PMCID: PMC3061492.
    63. Kompella UB, Kadam RS, Lee VH. Recent advances in ophthalmic drug delivery. Ther Deliv. 2010 Sep; 1(3):435-56. PMID: 21399724.
      View in: PubMed
    64. Durairaj C, Kadam RS, Chandler JW, Hutcherson SL, Kompella UB. Nanosized dendritic polyguanidilyated translocators for enhanced solubility, permeability, and delivery of gatifloxacin. Invest Ophthalmol Vis Sci. 2010 Nov; 51(11):5804-16. PMID: 20484584.
      View in: PubMed
    65. Rao VR, Prescott E, Shelke NB, Trivedi R, Thomas P, Struble C, Gadek T, O'Neill CA, Kompella UB. Delivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin (STZ) model of diabetic retinopathy (DR). Invest Ophthalmol Vis Sci. 2010 Oct; 51(10):5198-204. PMID: 20445119; PMCID: PMC3066602.
    66. Amrite A, Pugazhenthi V, Cheruvu N, Kompella U. Delivery of celecoxib for treating diseases of the eye: influence of pigment and diabetes. Expert Opin Drug Deliv. 2010 May; 7(5):631-45. PMID: 20205602; PMCID: PMC2858240.
    67. Missel P, Chastain J, Mitra A, Kompella U, Kansara V, Duvvuri S, Amrite A, Cheruvu N. In vitro transport and partitioning of AL-4940, active metabolite of angiostatic agent anecortave acetate, in ocular tissues of the posterior segment. J Ocul Pharmacol Ther. 2010 Apr; 26(2):137-46. PMID: 20415622; PMCID: PMC3158576.
    68. Trivedi R, Kompella UB. Nanomicellar formulations for sustained drug delivery: strategies and underlying principles. Nanomedicine (Lond). 2010 Apr; 5(3):485-505. PMID: 20394539; PMCID: PMC2902878.
    69. Mayo AS, Ambati BK, Kompella UB. Gene delivery nanoparticles fabricated by supercritical fluid extraction of emulsions. Int J Pharm. 2010 Mar 15; 387(1-2):278-85. PMID: 20025945; PMCID: PMC2830003.
    70. Kadam RS, Kompella UB. Influence of lipophilicity on drug partitioning into sclera, choroid-retinal pigment epithelium, retina, trabecular meshwork, and optic nerve. J Pharmacol Exp Ther. 2010 Mar; 332(3):1107-20. PMID: 19926800; PMCID: PMC2835449.
    71. Sundaram S, Trivedi R, Durairaj C, Ramesh R, Ambati BK, Kompella UB. Targeted drug and gene delivery systems for lung cancer therapy. Clin Cancer Res. 2009 Dec 01; 15(23):7299-308. PMID: 19920099; PMCID: PMC2787834.
    72. Sunkara G, Ayalasomayajula SP, DeRuiter J, Kompella UB. Probenecid treatment enhances retinal and brain delivery of N-4-benzoylaminophenylsulfonylglycine: an anionic aldose reductase inhibitor. Brain Res Bull. 2010 Feb 15; 81(2-3):327-32. PMID: 19761819; PMCID: PMC2814973.
    73. Kang SJ, Durairaj C, Kompella UB, O'Brien JM, Grossniklaus HE. Subconjunctival nanoparticle carboplatin in the treatment of murine retinoblastoma. Arch Ophthalmol. 2009 Aug; 127(8):1043-7. PMID: 19667343; PMCID: PMC2726977.
    74. Barañano DE, Kim SJ, Edelhauser HF, Durairaj C, Kompella UB, Handa JT. Efficacy and pharmacokinetics of intravitreal non-steroidal anti-inflammatory drugs for intraocular inflammation. Br J Ophthalmol. 2009 Oct; 93(10):1387-90. PMID: 19628498.
      View in: PubMed
    75. Sundaram S, Roy SK, Ambati BK, Kompella UB. Surface-functionalized nanoparticles for targeted gene delivery across nasal respiratory epithelium. FASEB J. 2009 Nov; 23(11):3752-65. PMID: 19608628; PMCID: PMC2775002.
    76. Durairaj C, Kim SJ, Edelhauser HF, Shah JC, Kompella UB. Influence of dosage form on the intravitreal pharmacokinetics of diclofenac. Invest Ophthalmol Vis Sci. 2009 Oct; 50(10):4887-97. PMID: 19516015; PMCID: PMC2767111.
    77. Sundaram S, Durairaj C, Kadam R, Kompella UB. Luteinizing hormone-releasing hormone receptor-targeted deslorelin-docetaxel conjugate enhances efficacy of docetaxel in prostate cancer therapy. Mol Cancer Ther. 2009 Jun; 8(6):1655-65. PMID: 19509261.
      View in: PubMed
    78. Park K, Chen Y, Hu Y, Mayo AS, Kompella UB, Longeras R, Ma JX. Nanoparticle-mediated expression of an angiogenic inhibitor ameliorates ischemia-induced retinal neovascularization and diabetes-induced retinal vascular leakage. Diabetes. 2009 Aug; 58(8):1902-13. PMID: 19491211; PMCID: PMC2712783.
    79. Ayalasomayajula SP, Ashton P, Kompella UB. Fluocinolone inhibits VEGF expression via glucocorticoid receptor in human retinal pigment epithelial (ARPE-19) cells and TNF-alpha-induced angiogenesis in chick chorioallantoic membrane (CAM). J Ocul Pharmacol Ther. 2009 Apr; 25(2):97-103. PMID: 19284324.
      View in: PubMed
    80. Kim ES, Durairaj C, Kadam RS, Lee SJ, Mo Y, Geroski DH, Kompella UB, Edelhauser HF. Human scleral diffusion of anticancer drugs from solution and nanoparticle formulation. Pharm Res. 2009 May; 26(5):1155-61. PMID: 19194787.
      View in: PubMed
    81. Singh SR, Grossniklaus HE, Kang SJ, Edelhauser HF, Ambati BK, Kompella UB. Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV. Gene Ther. 2009 May; 16(5):645-59. PMID: 19194480; PMCID: PMC2993697.
    82. Kadam RS, Kompella UB. Cassette analysis of eight beta-blockers in bovine eye sclera, choroid-RPE, retina, and vitreous by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Jan 15; 877(3):253-60. PMID: 19117816.
      View in: PubMed
    83. Cheruvu NP, Amrite AC, Kompella UB. Effect of diabetes on transscleral delivery of celecoxib. Pharm Res. 2009 Feb; 26(2):404-14. PMID: 18987961.
      View in: PubMed
    84. Sundaram S, Roy SK, Kompella UB. Differential expression of LHRH-receptor in bovine nasal tissue and its role in deslorelin delivery. Peptides. 2009 Feb; 30(2):351-8. PMID: 18992782.
      View in: PubMed
    85. Durairaj C, Shah JC, Senapati S, Kompella UB. Prediction of vitreal half-life based on drug physicochemical properties: quantitative structure-pharmacokinetic relationships (QSPKR). Pharm Res. 2009 May; 26(5):1236-60. PMID: 18841448.
      View in: PubMed
    86. Kratzer A, Buchebner M, Pfeifer T, Becker TM, Uray G, Miyazaki M, Miyazaki-Anzai S, Ebner B, Chandak PG, Kadam RS, Calayir E, Rathke N, Ahammer H, Radovic B, Trauner M, Hoefler G, Kompella UB, Fauler G, Levi M, Levak-Frank S, Kostner GM, Kratky D. Synthetic LXR agonist attenuates plaque formation in apoE-/- mice without inducing liver steatosis and hypertriglyceridemia. J Lipid Res. 2009 Feb; 50(2):312-26. PMID: 18812595; PMCID: PMC2636920.
    87. Christie JG, Kompella UB. Ophthalmic light sensitive nanocarrier systems. Drug Discov Today. 2008 Feb; 13(3-4):124-34. PMID: 18275910; PMCID: PMC2274995.
    88. Amrite AC, Edelhauser HF, Singh SR, Kompella UB. Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration. Mol Vis. 2008 Jan 29; 14:150-60. PMID: 18334929; PMCID: PMC2254958.
    89. Amrite AC, Edelhauser HF, Kompella UB. Modeling of corneal and retinal pharmacokinetics after periocular drug administration. Invest Ophthalmol Vis Sci. 2008 Jan; 49(1):320-32. PMID: 18172109; PMCID: PMC3324093.
    90. Cheruvu NP, Amrite AC, Kompella UB. Effect of eye pigmentation on transscleral drug delivery. Invest Ophthalmol Vis Sci. 2008 Jan; 49(1):333-41. PMID: 18172110; PMCID: PMC3324932.
    91. Amrite AC, Kompella UB. Celecoxib inhibits proliferation of retinal pigment epithelial and choroid-retinal endothelial cells by a cyclooxygenase-2-independent mechanism. J Pharmacol Exp Ther. 2008 Feb; 324(2):749-58. PMID: 18032574.
      View in: PubMed
    92. Kompella UB. Drug delivery to the back of the eye. Arch Soc Esp Oftalmol. 2007 Nov; 82(11):667-8; 669-70. PMID: 17979032.
      View in: PubMed
    93. Mo Y, Barnett ME, Takemoto D, Davidson H, Kompella UB. Human serum albumin nanoparticles for efficient delivery of Cu, Zn superoxide dismutase gene. Mol Vis. 2007 May 23; 13:746-57. PMID: 17563725; PMCID: PMC2768759.
    94. Raghava S, Kompella UB. AQ4, an antitumor anthracenedione, inhibits endothelial cell proliferation and vascular endothelial growth factor secretion: implications for the therapy of ocular neovascular disorders. Eur J Pharmacol. 2007 Jul 30; 568(1-3):68-74. PMID: 17543940.
      View in: PubMed
    95. Jani PD, Singh N, Jenkins C, Raghava S, Mo Y, Amin S, Kompella UB, Ambati BK. Nanoparticles sustain expression of Flt intraceptors in the cornea and inhibit injury-induced corneal angiogenesis. Invest Ophthalmol Vis Sci. 2007 May; 48(5):2030-6. PMID: 17460257.
      View in: PubMed
    96. Kador PF, Randazzo J, Babb T, Koushik K, Takamura Y, Zhu W, Blessing K, Kompella UB. Topical aldose reductase inhibitor formulations for effective lens drug delivery in a rat model for sugar cataracts. J Ocul Pharmacol Ther. 2007 Apr; 23(2):116-23. PMID: 17444799.
      View in: PubMed
    97. Marra M, Gukasyan HJ, Raghava S, Kompella UB. 2nd Ophthalmic Drug Development and Delivery Summit. Expert Opin Drug Deliv. 2007 Jan; 4(1):77-85. PMID: 17184164.
      View in: PubMed
    98. Kompella UB, Sundaram S, Raghava S, Escobar ER. Luteinizing hormone-releasing hormone agonist and transferrin functionalizations enhance nanoparticle delivery in a novel bovine ex vivo eye model. Mol Vis. 2006 Oct 17; 12:1185-98. PMID: 17102798.
      View in: PubMed
    99. Cheruvu NP, Kompella UB. Bovine and porcine transscleral solute transport: influence of lipophilicity and the Choroid-Bruch's layer. Invest Ophthalmol Vis Sci. 2006 Oct; 47(10):4513-22. PMID: 17003447; PMCID: PMC3324974.
    100. Margalit E, Kugler LJ, Brumm MV, Meza JL, Kompella UB, Escobar ER, Christensen GR. The safety of intraocular ketorolac in rabbits. Invest Ophthalmol Vis Sci. 2006 May; 47(5):2093-9. PMID: 16639020.
      View in: PubMed
    101. Amrite AC, Ayalasomayajula SP, Cheruvu NP, Kompella UB. Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage. Invest Ophthalmol Vis Sci. 2006 Mar; 47(3):1149-60. PMID: 16505053; PMCID: PMC3324981.
    102. Amrite AC, Kompella UB. Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration. J Pharm Pharmacol. 2005 Dec; 57(12):1555-63. PMID: 16354399.
      View in: PubMed
    103. Bandi N, Ayalasomayajula SP, Dhanda DS, Iwakawa J, Cheng PW, Kompella UB. Intratracheal budesonide-poly(lactide-co-glycolide) microparticles reduce oxidative stress, VEGF expression, and vascular leakage in a benzo(a)pyrene-fed mouse model. J Pharm Pharmacol. 2005 Jul; 57(7):851-60. PMID: 15969944.
      View in: PubMed
    104. Ayalasomayajula SP, Kompella UB. Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model. Eur J Pharmacol. 2005 Mar 28; 511(2-3):191-8. PMID: 15792788.
      View in: PubMed
    105. Raghava S, Hammond M, Kompella UB. Periocular routes for retinal drug delivery. Expert Opin Drug Deliv. 2004 Nov; 1(1):99-114. PMID: 16296723.
      View in: PubMed
    106. Ayalasomayajula SP, Kompella UB. Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration. Pharm Res. 2004 Oct; 21(10):1797-804. PMID: 15553225.
      View in: PubMed
    107. Bandi N, Wei W, Roberts CB, Kotra LP, Kompella UB. Preparation of budesonide- and indomethacin-hydroxypropyl-beta-cyclodextrin (HPBCD) complexes using a single-step, organic-solvent-free supercritical fluid process. Eur J Pharm Sci. 2004 Oct; 23(2):159-68. PMID: 15451004.
      View in: PubMed
    108. Ayalasomayajula SP, Amrite AC, Kompella UB. Inhibition of cyclooxygenase-2, but not cyclooxygenase-1, reduces prostaglandin E2 secretion from diabetic rat retinas. Eur J Pharmacol. 2004 Sep 13; 498(1-3):275-8. PMID: 15364005.
      View in: PubMed
    109. Koushik K, Dhanda DS, Cheruvu NP, Kompella UB. Pulmonary delivery of deslorelin: large-porous PLGA particles and HPbetaCD complexes. Pharm Res. 2004 Jul; 21(7):1119-26. PMID: 15290850.
      View in: PubMed
    110. Koushik KN, Kompella UB. Transport of deslorelin, an LHRH agonist, is vectorial and exhibits regional variation in excised bovine nasal tissue. J Pharm Pharmacol. 2004 Jul; 56(7):861-8. PMID: 15233864.
      View in: PubMed
    111. Koushik K, Bandi N, Sundaram S, Kompella UB. Evidence for LHRH-receptor expression in human airway epithelial (Calu-3) cells and its role in the transport of an LHRH agonist. Pharm Res. 2004 Jun; 21(6):1034-46. PMID: 15212170.
      View in: PubMed
    112. Koushik K, Kompella UB. Preparation of large porous deslorelin-PLGA microparticles with reduced residual solvent and cellular uptake using a supercritical carbon dioxide process. Pharm Res. 2004 Mar; 21(3):524-35. PMID: 15070105.
      View in: PubMed
    113. Sunkara G, Ayalasomayajula SP, Rao CS, Vennerstrom JL, DeRuiter J, Kompella UB. Systemic and ocular pharmacokinetics of N-4-benzoylaminophenylsulfonylglycine (BAPSG), a novel aldose reductase inhibitor. J Pharm Pharmacol. 2004 Mar; 56(3):351-8. PMID: 15025860; PMCID: PMC4469078.
    114. Aukunuru JV, Ayalasomayajula SP, Kompella UB. Nanoparticle formulation enhances the delivery and activity of a vascular endothelial growth factor antisense oligonucleotide in human retinal pigment epithelial cells. J Pharm Pharmacol. 2003 Sep; 55(9):1199-206. PMID: 14604462.
      View in: PubMed
    115. Koushik K, Sunkara G, Gwilt P, Kompella UB. Pathways and kinetics of deslorelin degradation in an airway epithelial cell line (Calu-1). Pharm Res. 2003 May; 20(5):779-87. PMID: 12751634.
      View in: PubMed
    116. Kompella UB, Bandi N, Ayalasomayajula SP. Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest Ophthalmol Vis Sci. 2003 Mar; 44(3):1192-201. PMID: 12601049.
      View in: PubMed
    117. Ayalasomayajula SP, Kompella UB. Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. Eur J Pharmacol. 2003 Jan 05; 458(3):283-9. PMID: 12504784.
      View in: PubMed
    118. Zhang L, Parsons DL, Navarre C, Kompella UB. Development and in-vitro evaluation of sustained release poloxamer 407 (P407) gel formulations of ceftiofur. J Control Release. 2002 Dec 13; 85(1-3):73-81. PMID: 12480313.
      View in: PubMed
    119. Wenzel JG, Balaji KS, Koushik K, Navarre C, Duran SH, Rahe CH, Kompella UB. Pluronic F127 gel formulations of deslorelin and GnRH reduce drug degradation and sustain drug release and effect in cattle. J Control Release. 2002 Dec 13; 85(1-3):51-9. PMID: 12480311.
      View in: PubMed
    120. Ayalasomayajula SP, Kompella UB. Induction of vascular endothelial growth factor by 4-hydroxynonenal and its prevention by glutathione precursors in retinal pigment epithelial cells. Eur J Pharmacol. 2002 Aug 09; 449(3):213-20. PMID: 12167462.
      View in: PubMed
    121. Aukunuru JV, Sunkara G, Ayalasomayajula SP, DeRuiter J, Clark RC, Kompella UB. A biodegradable injectable implant sustains systemic and ocular delivery of an aldose reductase inhibitor and ameliorates biochemical changes in a galactose-fed rat model for diabetic complications. Pharm Res. 2002 Mar; 19(3):278-85. PMID: 11934234.
      View in: PubMed
    122. Bandi N, Kompella UB. Budesonide reduces multidrug resistance-associated protein 1 expression in an airway epithelial cell line (Calu-1). Eur J Pharmacol. 2002 Feb 15; 437(1-2):9-17. PMID: 11864633.
      View in: PubMed
    123. Martin TM, Bandi N, Shulz R, Roberts CB, Kompella UB. Preparation of budesonide and budesonide-PLA microparticles using supercritical fluid precipitation technology. AAPS PharmSciTech. 2002; 3(3):E18. PMID: 12916933; PMCID: PMC2784047.
    124. Koushik KN, Bandi N, Kompella UB. Interaction of [D-Trp6, Des-Gly10] LHRH ethylamide and hydroxy propyl beta-cyclodextrin (HPbetaCD): thermodynamics of interaction and protection from degradation by alpha-chymotrypsin. Pharm Dev Technol. 2001 Nov; 6(4):595-606. PMID: 11775960.
      View in: PubMed
    125. Sunkara G, Kompella UB. Controlled release of bioactive materials--28th international symposium. Carbohydrate drug carriers: cyclodextrins and chitosans. IDrugs. 2001 Sep; 4(9):1014-6. PMID: 15965845.
      View in: PubMed
    126. Bandi N, Kompella UB. Budesonide reduces vascular endothelial growth factor secretion and expression in airway (Calu-1) and alveolar (A549) epithelial cells. Eur J Pharmacol. 2001 Aug 10; 425(2):109-16. PMID: 11502275.
      View in: PubMed
    127. Aukunuru JV, Sunkara G, Bandi N, Thoreson WB, Kompella UB. Expression of multidrug resistance-associated protein (MRP) in human retinal pigment epithelial cells and its interaction with BAPSG, a novel aldose reductase inhibitor. Pharm Res. 2001 May; 18(5):565-72. PMID: 11465409.
      View in: PubMed
    128. Kompella UB, Lee VH. Delivery systems for penetration enhancement of peptide and protein drugs: design considerations. Adv Drug Deliv Rev. 2001 Mar 01; 46(1-3):211-45. PMID: 11259842.
      View in: PubMed
    129. Kompella UB, Koushik K. Preparation of drug delivery systems using supercritical fluid technology. Crit Rev Ther Drug Carrier Syst. 2001; 18(2):173-99. PMID: 11325031.
      View in: PubMed
    130. Sunkara G, Deruiter J, Clark CR, Kompella UB. In-vitro hydrolysis, permeability, and ocular uptake of prodrugs of N-[4-(benzoylamino)phenylsulfonyl]glycine, a novel aldose reductase inhibitor. J Pharm Pharmacol. 2000 Sep; 52(9):1113-22. PMID: 11045892.
      View in: PubMed
    131. Ayalasomayajula SP, Kompella UB. Drug efflux pumps: challenges and opportunities. 14-18 November 1999, New Orleans, LA, USA. IDrugs. 2000 Feb; 3(2):148-9. PMID: 16107925.
      View in: PubMed
    132. Kompella UB, Sunkara G, Thomas E, Clark CR, Deruiter J. Rabbit corneal and conjunctival permeability of the novel aldose reductase inhibitors: N-[[4-(benzoylamino)phenyl] sulphonyl]glycines and N-benzoyl-N-phenylglycines. J Pharm Pharmacol. 1999 Aug; 51(8):921-7. PMID: 10504031.
      View in: PubMed
    133. Sunkara G, Navarre CB, Kompella UB. Influence of pH and temperature on kinetics of ceftiofur degradation in aqueous solutions. J Pharm Pharmacol. 1999 Mar; 51(3):249-55. PMID: 10344624.
      View in: PubMed
    134. Navarre CB, Zhang L, Sunkara G, Duran SH, Kompella UB. Ceftiofur distribution in plasma and joint fluid following regional limb injection in cattle. J Vet Pharmacol Ther. 1999 Feb; 22(1):13-9. PMID: 10211712.
      View in: PubMed
    135. Kompella UB. Drug delivery applications of supercritical fluid technology. IDrugs. 1999 Jan; 2(1):33-4. PMID: 16180167.
      View in: PubMed
    136. Kompella UB. Disposition of non-viral gene delivery systems and oligonucleotides. IDrugs. 1999 Jan; 2(1):31-2. PMID: 16180166.
      View in: PubMed
    137. Mathison S, Nagilla R, Kompella UB. Nasal route for direct delivery of solutes to the central nervous system: fact or fiction? J Drug Target. 1998; 5(6):415-41. PMID: 9783675.
      View in: PubMed
    138. Dani BA, Kompella UB. Inhibition of corneal metabolism of deslorelin by EDTA and ZnCl2. Drug Dev Ind Pharm. 1998 Jan; 24(1):11-7. PMID: 15605592.
      View in: PubMed
    139. Kompella UB, Dani BA. Metabolism of [des-Gly10, D-Trp6]LHRH ethylamide in the rabbit conjunctiva. J Ocul Pharmacol Ther. 1997 Apr; 13(2):163-70. PMID: 9090616.
      View in: PubMed
    140. Hosoya K, Kompella UB, Kim KJ, Lee VH. Contribution of Na(+)-glucose cotransport to the short-circuit current in the pigmented rabbit conjunctiva. Curr Eye Res. 1996 Apr; 15(4):447-51. PMID: 8670745.
      View in: PubMed
    141. Kompella UB, Dani BA. Metabolism of [Des-Gly10,D-Trp6]LHRH ethylamide in rabbit nasal tissue. Life Sci. 1996; 58(24):2201-7. PMID: 8649206.
      View in: PubMed
    142. Kompella UB, Kim KJ, Shiue MH, Lee VH. Cyclic AMP modulation of active ion transport in the pigmented rabbit conjunctiva. J Ocul Pharmacol Ther. 1996; 12(3):281-7. PMID: 8875334.
      View in: PubMed
    143. Kompella UB, Kim KJ, Shiue MH, Lee VH. Possible existence of Na(+)-coupled amino acid transport in the pigmented rabbit conjunctiva. Life Sci. 1995; 57(15):1427-31. PMID: 7674833.
      View in: PubMed
    144. Kompella UB, Kim KJ, Lee VH. Active chloride transport in the pigmented rabbit conjunctiva. Curr Eye Res. 1993 Dec; 12(12):1041-8. PMID: 7511088.
      View in: PubMed
    145. Lee YH, Kompella UB, Lee VH. Systemic absorption pathways of topically applied beta adrenergic antagonists in the pigmented rabbit. Exp Eye Res. 1993 Sep; 57(3):341-9. PMID: 7901046.
      View in: PubMed
    146. Lee VH, Yamamoto A, Kompella UB. Mucosal penetration enhancers for facilitation of peptide and protein drug absorption. Crit Rev Ther Drug Carrier Syst. 1991; 8(2):91-192. PMID: 1934087.
      View in: PubMed
    Kompella's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _

    Copyright © 2017 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.10.0)